[go: up one dir, main page]

BE2012C047I2 - - Google Patents

Download PDF

Info

Publication number
BE2012C047I2
BE2012C047I2 BE2012C047C BE2012C047C BE2012C047I2 BE 2012C047 I2 BE2012C047 I2 BE 2012C047I2 BE 2012C047 C BE2012C047 C BE 2012C047C BE 2012C047 C BE2012C047 C BE 2012C047C BE 2012C047 I2 BE2012C047 I2 BE 2012C047I2
Authority
BE
Belgium
Prior art keywords
drug
disclosed
compounds
ligand
linker
Prior art date
Application number
BE2012C047C
Other languages
French (fr)
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of BE2012C047I2 publication Critical patent/BE2012C047I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.
BE2012C047C 2002-07-31 2012-10-31 BE2012C047I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40040302P 2002-07-31 2002-07-31
PCT/US2003/024209 WO2004010957A2 (en) 2002-07-31 2003-07-31 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease

Publications (1)

Publication Number Publication Date
BE2012C047I2 true BE2012C047I2 (en) 2022-08-09

Family

ID=31188683

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2012C047C BE2012C047I2 (en) 2002-07-31 2012-10-31

Country Status (16)

Country Link
US (5) US7659241B2 (en)
EP (3) EP1545613B9 (en)
JP (1) JP4741838B2 (en)
AT (1) ATE516818T1 (en)
AU (2) AU2003263964C1 (en)
BE (1) BE2012C047I2 (en)
CA (2) CA2494105C (en)
CY (2) CY1111894T1 (en)
DK (2) DK2357006T3 (en)
ES (3) ES2556641T3 (en)
FR (1) FR12C0066I2 (en)
HU (2) HUE027549T2 (en)
LU (1) LU92133I2 (en)
PT (2) PT2357006E (en)
SI (2) SI1545613T1 (en)
WO (1) WO2004010957A2 (en)

Families Citing this family (777)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
ATE446317T1 (en) 2001-05-11 2009-11-15 Ludwig Inst For Cancer Res Ltd SPECIFIC BINDING PROTEINS AND THEIR USE
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
PT2357006E (en) 2002-07-31 2016-01-22 Seattle Genetics Inc Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004016733A2 (en) * 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2004073656A2 (en) 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
JP4838720B2 (en) 2003-05-13 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Methods for modulating metastasis and skeletal related phenomena caused by metastasis
PT1725249E (en) 2003-11-06 2014-04-10 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
WO2005082023A2 (en) * 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CA2558399C (en) * 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
US7641903B2 (en) * 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) * 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006044643A2 (en) * 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
JP2008519863A (en) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Auristatin having an aminobenzoic acid unit at the N-terminus
AU2005322410B2 (en) 2004-11-30 2011-11-10 Amgen Fremont Inc. Antibodies directed to GPNMB and uses thereof
US8165517B2 (en) 2005-01-19 2012-04-24 The Trustees Of The University Of Pennsylvania Methods for identifying inhibitors of vascular injury
CA2605507C (en) 2005-04-19 2016-06-28 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
PT1912677E (en) * 2005-06-20 2013-12-23 Psma Dev Company L L C Psma antibody-drug conjugates
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
EP2722051B1 (en) * 2005-07-07 2018-11-07 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
EP1901778A2 (en) * 2005-07-08 2008-03-26 Elan Pharmaceuticals Inc. Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds
EP1912671B1 (en) * 2005-07-18 2017-09-06 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
ES2527961T3 (en) 2005-09-26 2015-02-02 Medarex, L.L.C. Human monoclonal antibodies to CD70
AR059900A1 (en) 2006-03-17 2008-05-07 Genentech Inc ANTI-TAT226 ANTIBODIES AND IMMUNOCATE PLAYERS
AU2007253717A1 (en) * 2006-05-22 2007-11-29 Elan Pharmaceuticals, Inc. Preparation of polymer conjugates of therapeutic, agricultural and food additive compounds
BRPI0711249A2 (en) 2006-05-30 2012-03-13 Genentech, Inc. ANTIBODIES, POLYNUCLEOTIDES, VECTORS, HOST CELLS, METHODS FOR MANUFACTURING AN ANTIBODY, TO DETECTION THE PRESENCE OF CD2 IN A BIOLOGICAL SAMPLE, TO TREAT A PROLIFERATIVE B-CELL DIFFERENCE, CELL FOR PROLIBA CULAR, CELL FOR CIBLES ANTI-BODY DRUG CONJUGATE. IMMUNOCONJUGATES, PHARMACEUTICAL COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, ANTIBODY-DRUG CONJUGATE, ANTIBODY-DRUG CONJUGATE COMPOUNDS, B-CELL DETECTION TEST AND MANUFACTURING ARTICLE
US8257706B2 (en) * 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
ES2636089T3 (en) 2006-10-27 2017-10-05 Genentech, Inc. Antibodies and immunoconjugates and uses for them
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
EP2097534A4 (en) * 2006-12-14 2010-05-12 Medarex Inc Human antibodies that bind cd70 and uses thereof
CN110613845B (en) * 2007-01-25 2025-08-26 达娜-法勃肿瘤研究所公司 Use of anti-EGFR antibodies in treating diseases mediated by EGFR mutants
WO2008100805A2 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
ES2542152T3 (en) * 2007-03-15 2015-07-31 Ludwig Institute For Cancer Research Ltd. Treatment method using EGFR antibodies and Src inhibitors and related formulations
US8114967B2 (en) 2007-03-27 2012-02-14 Sea Lane Biotechnologies Llc Constructs and libraries comprising antibody surrogate light chain sequences
GB0707034D0 (en) * 2007-04-12 2007-05-23 St Andrews The Compounds
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
CN111499748A (en) 2007-07-16 2020-08-07 健泰科生物技术公司 Anti-CD79B antibodies and immunoconjugates and methods of use
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
EP3388086B1 (en) 2007-08-17 2020-10-07 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
JP5496897B2 (en) 2007-10-04 2014-05-21 ザイモジェネティクス， インコーポレイテッド B7 family member zB7H6 and related compositions and methods
EP2211885B1 (en) 2007-10-12 2015-07-29 Seattle Genetics, Inc. Combination therapy with antibody-drug conjugates
CN101903403B (en) * 2007-10-19 2016-03-16 西雅图基因公司 CD19 bonding agent and application thereof
EP3115469B1 (en) 2007-11-19 2020-04-29 Celera Corporation Lung cancer markers and uses thereof
EP2078492A1 (en) * 2008-01-11 2009-07-15 Roche Diagnostics GmbH Tape cassette for a medical hand device and blood sugar measuring system
AU2009205995B2 (en) 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
ES2587392T3 (en) 2008-01-31 2016-10-24 Genentech, Inc. Anti-CD79b and immunoconjugate antibodies and methods of use
PL2265283T3 (en) * 2008-03-18 2015-03-31 Seattle Genetics Inc Auristatin drug linker conjugates
KR101674097B1 (en) 2008-04-11 2016-11-08 시애틀 지네틱스, 인크. Detection and tratment of pancreatic, ovarian and other cancers
CA2722696C (en) 2008-04-30 2021-08-10 Immunogen, Inc. Cross-linkers and their uses
PL2282773T3 (en) 2008-05-02 2014-08-29 Seattle Genetics Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
DK2326350T3 (en) 2008-09-08 2013-12-16 Psma Dev Company L L C RELATIONS TO KILL PSMA EXPRESSING TAXAN RESISTANT CANCER CELLS
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
CA3159253A1 (en) 2009-01-09 2010-07-15 Seagen Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2403524A4 (en) * 2009-03-06 2012-09-26 Agensys Inc Antibody drug conjugates (adc) that bind to 24p4c12 proteins
WO2010126551A1 (en) 2009-04-30 2010-11-04 Immunogen, Inc. Potent conjugates and hydrophilic linkers
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
RS58810B1 (en) 2009-06-03 2019-07-31 Immunogen Inc Conjugation methods
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2775350A1 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
ES2788457T3 (en) 2009-10-23 2020-10-21 Millennium Pharm Inc Anti-GCC Antibody Molecules and Related Compositions and Methods
AU2010324686B2 (en) 2009-11-30 2016-05-19 Genentech, Inc. Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
DK2510011T3 (en) 2009-12-09 2014-12-01 Inst Nat Santé Et De La Rech Médicale MONOCLONAL ANTIBODIES BINDING B7H6 AND APPLICATIONS THEREOF
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CN102844045A (en) 2010-02-08 2012-12-26 艾更斯司股份有限公司 Antibody Drug Conjugate (ADC) Conjugated to 161P2F10B Protein
PE20130214A1 (en) 2010-02-23 2013-03-11 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
PL2542576T3 (en) * 2010-03-02 2016-10-31 Methods for screening antibodies
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CN107019804A (en) 2010-04-15 2017-08-08 西雅图基因公司 Target the tall and erect conjugate of Pyrrolobenzodiazepines
EP3549963B1 (en) 2010-04-15 2022-01-12 Kodiak Sciences Inc. High molecular weight zwitterion-containing polymers
BR112012026410B8 (en) 2010-04-15 2023-01-31 Spirogen Dev Sarl COMPOUND AND CONJUGATE OF PYROLOBENZODIAZEPINE AND USES THEREOF
SG185430A1 (en) 2010-06-03 2012-12-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
CN103068406B (en) 2010-06-08 2017-06-30 基因泰克公司 Cysteine Engineered Antibodies and Conjugates
PL2580243T3 (en) 2010-06-09 2020-05-18 Genmab A/S Antibodies against human cd38
JP5791707B2 (en) 2010-06-10 2015-10-07 シアトル ジェネティックス， インコーポレイテッド Novel auristatin derivatives and uses thereof
NZ604718A (en) 2010-06-15 2015-01-30 Genmab As Human antibody drug conjugates against tissue factor
DK3029066T3 (en) 2010-07-29 2019-05-20 Xencor Inc ANTIBODIES WITH MODIFIED ISOELECTRIC ITEMS
KR101851746B1 (en) 2010-09-29 2018-04-24 어젠시스 인코포레이티드 Antibody drug conjugates (adc) that bind to 191p4d12 proteins
JP5933562B2 (en) 2010-09-29 2016-06-15 シアトル ジェネティックス， インコーポレイテッド N-carboxyalkyl-auristatin and uses thereof
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
ES2730941T7 (en) 2010-10-22 2020-05-27 Seattle Genetics Inc Synergistic effects between auristatin-based antibody-drug conjugate conjugates and PI3K-AKT-mTOR pathway inhibitors
KR20220011811A (en) 2010-12-06 2022-01-28 씨젠 인크. Humanized antibodies to liv-1 and use of same to treat cancer
AU2011349443B2 (en) 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-CD38 . antibody
KR20140016262A (en) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
CN103764667B (en) 2011-03-16 2017-06-20 西雅图基因公司 N-carboxyalkyl auristatins and their applications
CN110038135B (en) 2011-03-17 2021-03-05 伯明翰大学 redirected immunotherapy
WO2012135440A1 (en) 2011-03-30 2012-10-04 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof
EP2699260B1 (en) 2011-04-20 2024-11-20 Genmab A/S Bispecifc antibodies against her2
CA2832387A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
US20140127240A1 (en) 2011-04-21 2014-05-08 Bayer Pharma Aktiengesellschaft Novel Binder-Drug Conjugates (ADCs) and Use of Same
KR101992502B1 (en) 2011-05-12 2019-06-24 제넨테크, 인크. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
US9790253B2 (en) 2011-05-19 2017-10-17 President And Fellows Of Harvard College OSW-1 analogs and conjugates, and uses thereof
KR102101806B1 (en) 2011-05-19 2020-04-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Anti-human-her3 antibodies and uses thereof
UA112434C2 (en) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед ANTIGENCY BINDING SPECIFICALLY Binds to ALL
SI3415531T1 (en) 2011-05-27 2023-12-29 Glaxo Group Limited BCMA (CD269/TNFRSF17) - BINDING PROTEINS
KR102356286B1 (en) * 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
MX371526B (en) * 2011-05-27 2020-01-31 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives.
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP5926374B2 (en) 2011-06-10 2016-05-25 メルサナ セラピューティクス，インコーポレイティド Protein-polymer-drug conjugate
WO2012177837A2 (en) 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
US9409988B2 (en) 2011-06-22 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
CA2839508A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. METHOD FOR STRENGTHENING THE EFFECTORAL FUNCTION OF THE ORIGINAL POLYEPEPTIDE, ITS OPTIONS AND THEIR APPLICATIONS
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
CN103987718A (en) 2011-09-20 2014-08-13 斯皮罗根有限公司 Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
US9958455B2 (en) 2011-09-29 2018-05-01 Seattle Genetics, Inc. Intact mass determination of protein conjugated agent compounds
WO2013055809A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
AU2012322932B2 (en) 2011-10-14 2016-11-10 Medimmune Limited Pyrrolobenzodiazepines
CN103987384A (en) 2011-10-14 2014-08-13 西雅图基因公司 Pyrrolobenzodiazepines and targeted conjugates
KR101961976B1 (en) 2011-10-14 2019-03-25 시애틀 지네틱스, 인크. Pyrrolobenzodiazepines and targeted conjugates
CA2850103C (en) 2011-10-14 2019-09-10 Spirogen Sarl Pyrrolobenzodiazepines
ES2657014T3 (en) 2011-11-17 2018-03-01 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
CA2857398A1 (en) * 2011-12-05 2013-06-13 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
WO2013096828A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US9764038B2 (en) 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
WO2013106773A2 (en) 2012-01-12 2013-07-18 Synaptics Incorporated Single layer capacitive imaging sensors
US20150011736A1 (en) 2012-01-20 2015-01-08 Sea Lane Biotechnologies, Llc Binding molecule conjugates
JP6602012B2 (en) 2012-02-10 2019-11-06 シアトル ジェネティクス インコーポレーテッド Detection and treatment of CD30 + cancer
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc ANTI-LGR5 AND IMMUNOCATE PLAYERS
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
KR20150006000A (en) 2012-05-01 2015-01-15 제넨테크, 인크. Anti-pmel17 antibodies and immunoconjugates
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
SG10201608904YA (en) 2012-05-15 2016-12-29 Seattle Genetics Inc Self-Stabilizing Linker Conjugates
US8822423B2 (en) * 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2013177055A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2611788T3 (en) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates thereof, methods for their preparation and methods for use
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
CN112587671A (en) 2012-07-18 2021-04-02 博笛生物科技有限公司 Targeted immunotherapy for cancer
ES2528892T3 (en) 2012-07-30 2015-02-13 Nbe-Therapeutics Llc Identification mediated by transposition of specific binding or functional proteins
WO2014022680A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
US9464141B2 (en) 2012-08-02 2016-10-11 Genentech, Inc. Anti-ETBR antibodies and immunoconjugates
EP2887959B1 (en) 2012-08-23 2018-12-19 Agensys, Inc. Antibody drug conjugates (adc) that bind to 158p1d7 proteins
HRP20190878T1 (en) 2012-08-31 2019-07-26 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
KR101995619B1 (en) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine-antibody conjugates
JP6367204B2 (en) 2012-10-12 2018-08-01 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
EP2839860B1 (en) 2012-10-12 2019-05-01 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
RS57694B1 (en) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
SMT201800346T1 (en) 2012-10-12 2018-09-13 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
PL2906251T3 (en) 2012-10-12 2018-02-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
SMT202100265T1 (en) 2012-10-12 2021-07-12 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2015004757A (en) * 2012-10-16 2015-07-17 Endocyte Inc Drug delivery conjugates containing unnatural amino acids and methods for using.
US9556192B2 (en) 2012-10-30 2017-01-31 Nerviano Medical Sciences S.R.L. Functionalized 9-bromo-camptothecin derivatives
JP6694712B2 (en) 2012-11-01 2020-05-20 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Antibody against CD269 (BCMA)
EP2917195B9 (en) 2012-11-05 2018-05-30 Pfizer Inc Spliceostatin analogs
EP3564259A3 (en) 2012-11-09 2020-02-12 Innate Pharma Recognition tags for tgase-mediated conjugation
KR20150104092A (en) 2012-11-15 2015-09-14 엔도사이트, 인코포레이티드 Conjugates for treating diseases caused by psma expressing cells
CN105849086B (en) 2012-11-24 2018-07-31 杭州多禧生物科技有限公司 Hydrophily chain junctor and its application on drug molecule and cell-binding molecules conjugation reaction
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2928503B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Conjugates of auristatin compounds
KR102227321B1 (en) 2012-12-12 2021-03-12 프로메가 코포레이션 Compositions and methods for capture of cellular targets of bioactive agents
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
AU2013364065B2 (en) * 2012-12-21 2018-10-04 Altrubio Inc. Hydrophilic self-immolative linkers and conjugates thereof
CN105188749B (en) 2012-12-21 2017-12-19 西雅图基因公司 Anti-NTB-A antibodies and related compositions and methods
EP2934596A1 (en) 2012-12-21 2015-10-28 Glykos Finland Oy Linker-payload molecule conjugates
KR20220156667A (en) 2013-01-10 2022-11-25 젠맵 비. 브이 Human igg1 fc region variants and uses thereof
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP2961435B1 (en) 2013-02-28 2019-05-01 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN105189552B (en) 2013-03-14 2019-08-02 基因泰克公司 Anti-B7-H4 Antibodies and Immunoconjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
HK1219044A1 (en) 2013-03-15 2017-03-24 艾伯维德国有限责任两合公司 Anti-egfr antibody drug conjugate formulations
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
HRP20191470T1 (en) 2013-03-15 2020-01-10 Xencor, Inc. Heterodimeric proteins
MX2015012562A (en) 2013-03-15 2016-06-21 Abbvie Inc Antibody drug conjugate (adc) purification.
US11072811B2 (en) 2013-03-15 2021-07-27 Promega Corporation Substrates for covalent tethering of proteins to functional groups or solid surfaces
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10168323B2 (en) 2013-03-15 2019-01-01 Promega Corporation Compositions and methods for capture of cellular targets of bioactive agents
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CN105358174B (en) 2013-03-15 2019-03-15 酵活有限公司 Cytotoxic and antimitotic compounds and methods for their use
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
WO2014177771A1 (en) 2013-05-02 2014-11-06 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
CA2910029A1 (en) 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
CN105358574B (en) 2013-05-31 2020-10-16 基因泰克公司 Anti-Wall Teichoic Acid Antibodies and Conjugates
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP3003387A1 (en) 2013-06-04 2016-04-13 Cytomx Therapeutics Inc. Compositions and methods for conjugating activatable antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
CA2914189C (en) 2013-06-21 2023-03-14 Innate Pharma Enzymatic conjugation of polypeptides
ES2658039T3 (en) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
SG11201600587VA (en) 2013-08-01 2016-02-26 Agensys Inc Antibody drug conjugates (adc) that bind to cd37 proteins
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
US9552089B2 (en) 2013-08-07 2017-01-24 Synaptics Incorporated Capacitive sensing using a matrix electrode pattern
BR112016002829A2 (en) 2013-08-12 2017-09-19 Genentech Inc COMPOUND AND PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATE COMPOUND, PHARMACEUTICAL COMPOSITION, CANCER TREATMENT METHOD, CANCER TREATMENT KIT, DRUG LINKER INTERMEDIATE, CBI DIMER DRUG MOUNT AND COMPOUND
WO2015031698A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Site-specific antibody conjugation methods and compositions
EA201600252A1 (en) 2013-09-12 2017-05-31 Галозим, Инк. MODIFIED ANTIBODIES TO RECEPTORS OF ANTIEPIDERMAL GROWTH FACTOR AND METHODS FOR THEIR USE
JP2016537399A (en) 2013-09-17 2016-12-01 ジェネンテック， インコーポレイテッド Method using anti-LGR5 antibody
US9298325B2 (en) 2013-09-30 2016-03-29 Synaptics Incorporated Processing system for a capacitive sensing device
US10042489B2 (en) 2013-09-30 2018-08-07 Synaptics Incorporated Matrix sensor for image touch sensing
US20150091842A1 (en) 2013-09-30 2015-04-02 Synaptics Incorporated Matrix sensor for image touch sensing
US9459367B2 (en) 2013-10-02 2016-10-04 Synaptics Incorporated Capacitive sensor driving technique that enables hybrid sensing or equalization
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
JP6420331B2 (en) 2013-10-11 2018-11-07 メルサナ セラピューティクス，インコーポレイティド Protein-polymer-drug conjugate
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
IL245009B (en) 2013-10-11 2022-08-01 Asana Biosciences Llc A bracelet consisting of drug, protein and polymer
HRP20210410T1 (en) 2013-10-11 2021-04-30 Oxford Bio Therapeutics Limited Conjugated antibodies against ly75 for the treatment of cancer
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
AU2014331667B2 (en) 2013-10-11 2019-08-22 Biomed Valley Discoveries, Inc. TEM8 antibodies and their use
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
AU2014337555C1 (en) * 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
AU2014337317A1 (en) 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
US9274662B2 (en) 2013-10-18 2016-03-01 Synaptics Incorporated Sensor matrix pad for performing multiple capacitive sensing techniques
SI4095130T1 (en) 2013-10-18 2024-05-31 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
SG11201603125SA (en) 2013-10-21 2016-05-30 Genentech Inc ANTI-Ly6E ANTIBODIES AND METHODS OF USE
US9495046B2 (en) 2013-10-23 2016-11-15 Synaptics Incorporated Parasitic capacitance filter for single-layer capacitive imaging sensors
US9081457B2 (en) 2013-10-30 2015-07-14 Synaptics Incorporated Single-layer muti-touch capacitive imaging sensor
US20160280798A1 (en) 2013-11-06 2016-09-29 The United States Of America, As Represented By The Secretary Department Of Health & Human Service Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CN105849125B (en) 2013-11-07 2020-05-15 国家医疗保健研究所 Neuregulin allosteric anti-HER3 antibody
AU2014348601A1 (en) 2013-11-14 2016-05-26 Endocyte, Inc. Compounds for positron emission tomography
AU2014352824B2 (en) 2013-11-25 2019-07-18 Seagen Inc. Preparing antibodies from CHO cell cultures for conjugation
JP6525474B2 (en) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Combination of Aurora kinase inhibitor and anti-CD30 antibody
PE20160712A1 (en) 2013-12-13 2016-07-26 Genentech Inc ANTI-CD33 ANTIBODIES AND IMMUNOCONJUGATES
CA2929565A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP4212181A3 (en) 2013-12-19 2023-11-15 Seagen Inc. Methylene carbamate linkers for use with targeted-drug conjugates
TWI727919B (en) 2013-12-19 2021-05-21 美商西雅圖遺傳學公司 Methylene carbamate linkers for use with targeted-drug conjugates
AU2014373640B2 (en) 2013-12-27 2018-08-30 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
JP2017503803A (en) 2014-01-10 2017-02-02 シャンハイ バーディー バイオテック インコーポレイテッド Compounds and compositions for treating EGFR expressing tumors
AU2015206515B2 (en) 2014-01-15 2019-12-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cartilage targeting agents and their use
JP2017505305A (en) 2014-01-24 2017-02-16 ジェネンテック， インコーポレイテッド Methods using anti-STEAP1 antibodies and immunoconjugates
AU2015210578B2 (en) 2014-01-29 2020-04-16 Jiangsu Hengrui Medicine Co., Ltd. Ligand-cytotoxic drug conjugate, preparation method therefor, and uses thereof
FR3017298B1 (en) 2014-02-07 2016-03-04 Centre Nat Rech Scient CONJUGATES AND PRO-DRUGS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES
CN106456725B9 (en) 2014-02-11 2022-08-09 西雅图基因公司 Selective reduction of proteins
SG10202001468UA (en) 2014-02-17 2020-04-29 Seattle Genetics Inc Hydrophilic antibody-drug conjugates
KR20170008202A (en) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 Anti-dll3 antibodies and drug conjugates for use in melanoma
CN114262344A (en) 2014-02-28 2022-04-01 杭州多禧生物科技有限公司 Charged linkers and their use in conjugation reactions
US9798429B2 (en) 2014-02-28 2017-10-24 Synaptics Incorporated Guard electrodes in a sensing stack
SG11201607746QA (en) 2014-03-21 2016-10-28 Abbvie Inc Anti-egfr antibodies and antibody drug conjugates
JP6775422B2 (en) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Bispecific antibody that binds to CD38 and CD3
US10133421B2 (en) 2014-04-02 2018-11-20 Synaptics Incorporated Display stackups for matrix sensor
US9260478B2 (en) 2014-04-04 2016-02-16 Shanghui Hu Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
FR3020063A1 (en) 2014-04-16 2015-10-23 Gamamabs Pharma ANTI-HER4 HUMAN ANTIBODY
US9927832B2 (en) 2014-04-25 2018-03-27 Synaptics Incorporated Input device having a reduced border region
US9690397B2 (en) 2014-05-20 2017-06-27 Synaptics Incorporated System and method for detecting an active pen with a matrix sensor
US10328149B2 (en) 2014-06-13 2019-06-25 Tenboron Oy Conjugates comprising an anti-EGFR1 antibody
WO2015189478A1 (en) 2014-06-13 2015-12-17 Glykos Finland Oy Payload-polymer-protein conjugates
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
WO2015197919A1 (en) 2014-06-25 2015-12-30 Glykos Finland Oy Antibody drug conjugates binding to high-mannose n-glycan
CA2954934C (en) 2014-06-30 2023-09-26 Glykos Finland Oy Drug derivative and conjugates
CN105440135A (en) 2014-09-01 2016-03-30 博笛生物科技有限公司 Anti-PD-L1 conjugates for the treatment of tumors
DK3169706T3 (en) 2014-07-11 2020-03-09 Genmab As ANTIBODIES THAT BINDER AXL
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
WO2016014984A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
RU2744978C2 (en) 2014-07-24 2021-03-17 Дженентек, Инк. Methods for conjugation of agent with thiol group in protein comprising at least one trisulfide bond
DK4074735T3 (en) 2014-08-28 2025-07-14 Bioatla Inc CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS
US20170247412A1 (en) 2014-09-11 2017-08-31 Seattle Genetics, Inc. Targeted delivery of tertiary amine-containing drug substances
MX2017003126A (en) 2014-09-12 2017-08-28 Genentech Inc Anti-her2 antibodies and immunoconjugates.
CN113698485A (en) 2014-09-12 2021-11-26 基因泰克公司 anti-B7-H4 antibodies and immunoconjugates
CN107108724A (en) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11201701627PA (en) 2014-09-12 2017-03-30 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
RS62860B1 (en) 2014-09-17 2022-02-28 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
RS60349B8 (en) 2014-09-23 2022-10-31 Hoffmann La Roche Method of using anti-cd79b immunoconjugates
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
JP2017537893A (en) 2014-10-31 2017-12-21 アッヴィ・バイオセラピューティクス・インコーポレイテッド Anti-CS1 antibody and antibody drug conjugate
US20170312290A1 (en) 2014-11-05 2017-11-02 Nerviano Medical Sciences S.R.L. Functionalized morpholinyl anthracycline derivatives
SI3221349T1 (en) 2014-11-19 2021-02-26 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
CN104609464B (en) * 2014-11-21 2017-01-04 中国科学院电工研究所 A kind of preparation method of PbS nanometer sheet
CN107148285B (en) 2014-11-25 2022-01-04 Adc治疗股份有限公司 Pyrrolobenzodiazepine-antibody conjugates
AU2015353409B2 (en) 2014-11-26 2019-05-09 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10526417B2 (en) 2014-11-26 2020-01-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016090038A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
WO2016090040A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
EP3735990A1 (en) 2014-12-09 2020-11-11 Abbvie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
ES2764299T3 (en) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Human monoclonal antibodies against AXL
CN107223123A (en) 2014-12-09 2017-09-29 艾伯维公司 BCL‑XL Inhibitory Compounds with Low Cell Penetration and Antibody Drug Conjugates Comprising It
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
US10175827B2 (en) 2014-12-23 2019-01-08 Synaptics Incorporated Detecting an active pen using a capacitive sensing device
US9778713B2 (en) 2015-01-05 2017-10-03 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
TW201632532A (en) 2015-01-14 2016-09-16 必治妥美雅史谷比公司 Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
WO2016115191A1 (en) 2015-01-14 2016-07-21 Bristol-Myers Squibb Company Benzodiazepine dimers, conjugates thereof, and methods of making and using
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
CN107849090A (en) 2015-01-28 2018-03-27 索伦托医疗有限公司 Antibody drug conjugates
WO2016126611A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
WO2016141230A1 (en) 2015-03-05 2016-09-09 Sirenas Llc Cyclic peptide analogs and conjugates thereof
ES2884844T3 (en) 2015-03-09 2021-12-13 Agensys Inc Antibody Drug Conjugates (ADCs) That Bind to FLT3 Proteins
KR20170128256A (en) 2015-03-18 2017-11-22 시애틀 지네틱스, 인크. CD48 antibody and its conjugate
US9939972B2 (en) 2015-04-06 2018-04-10 Synaptics Incorporated Matrix sensor with via routing
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CN106188293A (en) 2015-04-17 2016-12-07 江苏恒瑞医药股份有限公司 Anti-C-met antibodies and anti-C-met antibodies-cytotoxic drug conjugate and medical usage thereof
EP3091033A1 (en) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
EP3295171A1 (en) 2015-05-12 2018-03-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and kits for labeling, detection and isolation of foxp3+ regulatory t cells, isolated population of foxp3+ regulatory t cells thus obtained and uses thereof
JP6770533B2 (en) 2015-05-22 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル A human monoclonal antibody fragment that inhibits both the catalytic activity of Cath-D and its binding to the LRP1 receptor.
EP3303391A1 (en) 2015-05-26 2018-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
WO2016189118A1 (en) 2015-05-28 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
WO2016201394A1 (en) 2015-06-12 2016-12-15 Miltenyi Biotec Technology, Inc. Method to treat cancer with engineered t-cells
AU2015242210A1 (en) 2015-06-15 2017-12-07 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers for conjugation
BR112017027258A2 (en) 2015-06-23 2018-08-28 Bristol-Myers Squibb Company macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
US9715304B2 (en) 2015-06-30 2017-07-25 Synaptics Incorporated Regular via pattern for sensor-based input device
EP4302784A3 (en) 2015-06-30 2024-03-13 Seagen Inc. Anti-ntb-a antibodies and related compositions and methods
US9720541B2 (en) 2015-06-30 2017-08-01 Synaptics Incorporated Arrangement of sensor pads and display driver pads for input device
US10095948B2 (en) 2015-06-30 2018-10-09 Synaptics Incorporated Modulation scheme for fingerprint sensing
JP6892431B2 (en) 2015-07-10 2021-06-23 ゲンマブ エー／エス AXL-Specific Antibodies-Drug Conjugates for Cancer Treatment
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
JP6858185B2 (en) 2015-07-22 2021-04-14 イナサリス Anti-TfR antibody and its use in the treatment of proliferative and inflammatory diseases
CN205028263U (en) 2015-09-07 2016-02-10 辛纳普蒂克斯公司 Capacitance sensor
US10037112B2 (en) 2015-09-30 2018-07-31 Synaptics Incorporated Sensing an active device'S transmission using timing interleaved with display updates
US10722593B2 (en) 2015-10-02 2020-07-28 Sirenas Llc Anti-cancer compounds and conjugates thereof
WO2017062748A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017062820A1 (en) 2015-10-09 2017-04-13 Miltenyi Biotec Technology, Inc. Chimeric antigen receptors and methods of use
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
US10556953B2 (en) 2015-10-12 2020-02-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
EP3165532B1 (en) * 2015-11-03 2018-12-19 Industrial Technology Research Institute Auristatin derivatives, linker-drugs and ligand-drug conjugates
DK3377103T4 (en) 2015-11-19 2025-05-19 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
JP2019500327A (en) 2015-11-30 2019-01-10 アッヴィ・インコーポレイテッド Anti-huLRRC15 antibody drug conjugate and method of use thereof
JP2019501124A (en) 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド Anti-huLRRC15 antibody drug conjugate and method of use thereof
TWI852735B (en) 2015-12-04 2024-08-11 美商思進公司 Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US10067587B2 (en) 2015-12-29 2018-09-04 Synaptics Incorporated Routing conductors in an integrated display device and sensing device
CN106933400B (en) 2015-12-31 2021-10-29 辛纳普蒂克斯公司 Single-layer sensor pattern and sensing method
CN108713026B (en) 2016-01-08 2023-01-06 美国全心医药生技股份有限公司 Tetravalent anti-PSGL-1 antibody and use thereof
SG11201805534TA (en) 2016-01-13 2018-07-30 Genmab As Formulation for antibody and drug conjugate thereof
UA125718C2 (en) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Ror1 antibody compositions and related methods
EA039072B9 (en) * 2016-01-25 2022-02-04 Регенерон Фармасьютикалз, Инк. MAITANZINOID DERIVATIVES, THEIR CONJUGATES AND METHODS OF APPLICATION
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
BR112018015238A2 (en) 2016-01-27 2018-12-18 Sutro Biopharma Inc antibody conjugate, antibody, kit, pharmaceutical composition, and methods for treating or preventing a disease or condition and for diagnosing a disease or condition
RS64219B1 (en) 2016-02-05 2023-06-30 Rigshospitalet ANTIBODY-DRUG CONJUGATES DIRECTED ACCORDING TO UPARAP
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20190194338A1 (en) 2016-02-17 2019-06-27 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
US11191821B2 (en) 2016-02-27 2021-12-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptide vaccine formulations and use thereof for inducing an immune response
TW201740979A (en) 2016-02-29 2017-12-01 瑪德瑞高製藥公司 HSP90 inhibitor drug conjugates
CN114191428B (en) * 2016-03-02 2024-09-24 卫材研究发展管理有限公司 Eribulin-based antibody-drug conjugates and methods of use
AR107800A1 (en) 2016-03-04 2018-06-06 Genentech Inc PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE
MA45324A (en) 2016-03-15 2019-01-23 Seattle Genetics Inc POLYTHERAPY USING ADC-LIV1 AND CHEMOTHERAPEUTIC AGENT
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
EP3433272A1 (en) 2016-03-22 2019-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Humanized anti-claudin-1 antibodies and uses thereof
US10913780B2 (en) 2016-03-24 2021-02-09 The Administrators Of The Tulane Educational Fund Conjugates, their compositions, their uses, and their methods of making
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINE LINKS AND INTERMEDIATES THEREOF
DK3438118T3 (en) 2016-03-29 2023-05-30 Toray Industries Peptide derivative and use thereof
MA45328A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
CN109563164A (en) 2016-04-15 2019-04-02 生物蛋白有限公司 Anti-AXL antibodies, antibody fragment and their immunoconjugates with and application thereof
CN109071634A (en) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 Antibody coupling matter and its preparation and application
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
MX394735B (en) 2016-05-13 2025-03-24 Bioatla Llc ANTI-ROR2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND THEIR USES.
MX2018014175A (en) 2016-05-17 2020-02-07 Abbvie Biotherapeutics Inc ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE.
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
EP3464294B1 (en) 2016-05-30 2022-07-13 Toxinvent Oü Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment
CN109476648B (en) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 Sevelamer antibody-drug conjugates and methods of use
JP2019521114A (en) 2016-06-08 2019-07-25 アッヴィ・インコーポレイテッド Anti-EGFR antibody drug conjugate
ES2861499T3 (en) 2016-06-08 2021-10-06 Abbvie Inc Anti-B7-H3 antibodies and antibody-drug conjugates
MX2018015268A (en) 2016-06-08 2019-08-12 Abbvie Inc Anti-cd98 antibodies and antibody drug conjugates.
CA3027044A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN109562168A (en) 2016-06-08 2019-04-02 艾伯维公司 Anti-CD98 Antibody and Antibody Drug Conjugate
BR112018075630A2 (en) 2016-06-08 2019-03-19 Abbvie Inc. anti-cd98 antibodies and antibody drug conjugates
MX2018015285A (en) 2016-06-08 2019-09-18 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates.
TW202320860A (en) 2016-06-08 2023-06-01 美商艾伯維有限公司 Anti-egfr antibody drug conjugates
BR112018075645A2 (en) 2016-06-08 2019-04-09 Abbvie Inc. anti-egfr drug antibody conjugates
CN110352070B (en) 2016-06-14 2024-09-17 Xencor股份有限公司 Bispecific checkpoint inhibitor antibodies
EP3474901B1 (en) 2016-06-27 2025-08-06 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
BR112019001945A2 (en) 2016-08-09 2019-05-07 Seattle Genetics, Inc. binder drug conjugate composition, pharmaceutically acceptable formulation, methods for treating a hyperproliferative disease or condition, for inhibiting the multiplication of a tumor cell or cancer cell, and for preparing a binder drug conjugate composition, and, compound
CN106674347B (en) * 2016-08-16 2019-12-13 滨州医学院 A Novel Otostatin Antibody
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11254705B2 (en) 2016-09-02 2022-02-22 Sirenas Llc Cyclic peptide analogs and conjugates thereof
ES2981703T3 (en) 2016-09-02 2024-10-10 Lentigen Tech Inc Compositions and methods for treating cancer with DuoCars
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CR20230179A (en) 2016-10-14 2023-06-12 Xencor Inc IL15/IL15Ra HETERODIMERIC FC-FUSION PROTEINS
SG11201903013SA (en) 2016-10-18 2019-05-30 Seattle Genetics Inc Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
AU2017345454B2 (en) 2016-10-19 2024-10-31 Invenra Inc. Antibody constructs
KR20190084264A (en) 2016-10-25 2019-07-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Monoclonal antibody that binds to the CD160 transverse soma
KR20190075921A (en) 2016-10-28 2019-07-01 도레이 카부시키가이샤 A pharmaceutical composition for the treatment and / or prevention of cancer
CA3041988A1 (en) 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof
US10711032B2 (en) 2016-11-08 2020-07-14 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
NZ752394A (en) 2016-11-14 2021-07-30 Hangzhou Dac Biotech Co Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
WO2018089890A1 (en) 2016-11-14 2018-05-17 Millennium Pharmaceuticals, Inc. Non-adult human dosing of anti-cd30 antibody-drug conjugates
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
JP7244987B2 (en) 2016-12-14 2023-03-23 シージェン インコーポレイテッド Multidrug Antibody Drug Conjugates
US10864279B2 (en) 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
CN110234348B (en) 2016-12-16 2024-06-25 蓝鳍生物医药公司 Anti-CUB domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates and methods of use thereof
BR112019013107A2 (en) 2016-12-22 2019-12-17 Università Degli Studi Magna Graecia Catanzaro antibodies, binding molecule, chimeric antigen receptor, expression vector, pharmaceutical composition, lymphocyte, nucleic acid, hybridoma cell, method for monoclonal antibody production and uses
KR102015524B1 (en) * 2016-12-26 2019-08-29 인터올리고 주식회사 [GRO Aptamer]-Drug Conjugates And Use Thereof
CN106854245A (en) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 Protein monoclonal antibody of AntiCD3 McAb 0 and application thereof
JP6706394B1 (en) 2017-01-09 2020-06-03 レンティジェン・テクノロジー・インコーポレイテッドＬｅｎｔｉｇｅｎ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． Compositions and methods for treating cancer by anti-mesothelin immunotherapy
JP6671555B2 (en) 2017-02-08 2020-03-25 アーデーセー セラピューティクス ソシエテ アノニム Pyrrolobenzodiazepine antibody conjugate
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
JP7341060B2 (en) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and pharmaceutical compositions for the treatment of cancer associated with MAPK pathway activation
EP3583125B1 (en) 2017-02-16 2025-01-22 Sonnet BioTherapeutics, Inc. Albumin binding domain fusion proteins
WO2018158716A1 (en) 2017-03-02 2018-09-07 Cadila Healthcare Limited Novel protein drug conjugate formulation
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
JP7137896B2 (en) 2017-03-24 2022-09-15 レンティジェン・テクノロジー・インコーポレイテッド Compositions and methods for treating cancer with anti-CD33 immunotherapy
SG11201908325PA (en) 2017-03-24 2019-10-30 Seattle Genetics Inc Process for the preparation of glucuronide drug-linkers and intermediates thereof
AU2018247767B2 (en) 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
EP3607319A1 (en) 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
CN110582505B (en) 2017-04-18 2021-04-02 免疫医疗有限公司 Pyrrolobenzodiazepine* conjugates
EP3612567B1 (en) 2017-04-19 2024-09-11 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
MX2019012464A (en) 2017-04-20 2019-12-11 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate.
US11931414B2 (en) 2017-04-27 2024-03-19 Seagen Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
JOP20190254A1 (en) 2017-04-27 2019-10-27 Pharma Mar Sa Antitumoral compounds
KR20240111015A (en) 2017-04-28 2024-07-16 아지노모토 가부시키가이샤 Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US11666657B2 (en) 2017-05-16 2023-06-06 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
WO2018213077A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
WO2018222675A1 (en) 2017-05-30 2018-12-06 The Board Of Regents Of The University Of Oklahoma Anti-doublecortin-like kinase 1 antibodies and methods of use
CN118994394A (en) 2017-06-12 2024-11-22 蓝鳍生物医药公司 Anti-IL 1RAP antibodies and antibody drug conjugates
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
CN108452321B (en) * 2017-06-19 2021-11-26 四川百利药业有限责任公司 Antibody-drug conjugate with acidic self-stabilizing joint
US20210403573A1 (en) 2017-06-22 2021-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
EP3641826B1 (en) 2017-06-22 2023-12-06 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
CN111587124B (en) 2017-06-23 2024-01-12 维洛斯生物股份有限公司 ROR1 antibody immunoconjugate
US11613588B2 (en) 2017-06-28 2023-03-28 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
CN111132733A (en) 2017-06-30 2020-05-08 Xencor股份有限公司 Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15R α and an antigen binding domain
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
JP7237926B2 (en) 2017-07-31 2023-03-13 レンティジェン・テクノロジー・インコーポレイテッド Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
BR112020001605A2 (en) 2017-08-09 2020-08-11 Juno Therapeutics Inc methods for producing genetically modified cell compositions and related compositions
ES2906965T3 (en) 2017-08-18 2022-04-21 Medimmune Ltd Pyrrolobenzodiazepine conjugates
ES2960419T3 (en) 2017-09-15 2024-03-04 Lentigen Tech Inc Compositions and methods of cancer treatment with anti-CD19 immunotherapy
SG11202002310UA (en) 2017-09-18 2020-04-29 Sutro Biopharma Inc Anti- folate receptor alpha antibody conjugates and their uses
EP3694559A2 (en) 2017-10-11 2020-08-19 Seattle Genetics, Inc. Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
WO2019074124A1 (en) 2017-10-12 2019-04-18 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
JP7275118B2 (en) 2017-10-16 2023-05-17 レンティジェン・テクノロジー・インコーポレイテッド Compositions and methods for treating cancer with anti-CD22 immunotherapy
CN107759699A (en) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 Transgenic T cell targeting CD30 antigen and its preparation method and application
WO2019089870A1 (en) 2017-11-01 2019-05-09 Seattle Genetics, Inc. Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
AU2018360031B2 (en) 2017-11-03 2025-08-21 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-ROR1 immunotherapy
US12134631B2 (en) 2017-11-07 2024-11-05 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
EP3706793A1 (en) 2017-11-08 2020-09-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3082549A1 (en) * 2017-11-22 2019-05-31 Seattle Genetics, Inc. Acid-mediated assay for analyzing ligand-drug conjugates
MX2020005473A (en) 2017-11-27 2020-08-27 Purdue Pharma Lp Humanized antibodies targeting human tissue factor.
BR112020010816A2 (en) * 2017-11-29 2020-11-10 Magenta Therapeutics, Inc. compositions and methods for the depletion of cd2 + cells
MX2020005463A (en) 2017-12-01 2020-09-07 Seattle Genetics Inc Cd47 antibodies and uses thereof for treating cancer.
EP3717518A1 (en) 2017-12-01 2020-10-07 Seattle Genetics, Inc. Humanized anti-liv1 antibodies for the treatment of breast cancer
CN111344402A (en) 2017-12-14 2020-06-26 Ezy生物科技有限公司 Subject-specific tumor suppressor cells and uses thereof
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
CN111655718B (en) 2017-12-19 2025-07-22 Xencor股份有限公司 Engineered IL-2 FC fusion proteins
US10894819B2 (en) 2017-12-20 2021-01-19 Lentigen Technology, Inc. Compositions and methods for treating HIV/AIDS with immunotherapy
CA3086926A1 (en) 2018-01-08 2019-07-11 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
AU2019225845B2 (en) * 2018-02-20 2024-06-20 Seagen Inc. Hydrophobic Auristatin F compounds and conjugates thereof
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
EP3762423A2 (en) 2018-03-07 2021-01-13 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates
CA3093477A1 (en) 2018-03-13 2019-09-19 Zymeworks Inc. Anti-her2 biparatopic antibody-drug conjugates and methods of use
JP2021518387A (en) 2018-03-19 2021-08-02 バイオヴェンチャーズ リミテッド ライアビリティ カンパニー Periostin antibody and how to use it
JP2021518397A (en) 2018-03-23 2021-08-02 シージェン インコーポレイテッド Use of antibody drug conjugates containing tubulin-destroying agents to treat solid tumors
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
JP2021521784A (en) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド PD-1 targeted heterodimer fusion proteins containing IL-15 / IL-15RaFc fusion proteins and PD-1 antigen binding domains and their use
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
WO2019212357A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
CA3099419A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
US11396497B2 (en) 2018-05-04 2022-07-26 New Mexico Tech University Research Park Corporation Proteasome inhibitors
BR112020022642A2 (en) 2018-05-07 2021-02-17 Genmab A/S method to treat cancer in an individual, and, kit
MX2020011176A (en) 2018-05-07 2020-11-12 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate.
MX2020011546A (en) 2018-05-09 2021-01-29 Regeneron Pharma Anti-msr1 antibodies and methods of use thereof.
BR112020024351A2 (en) 2018-06-01 2021-02-23 Novartis Ag binding molecules against bcma and uses thereof
IL322895A (en) 2018-06-05 2025-10-01 King S College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
TWI851577B (en) 2018-06-07 2024-08-11 美商思進公司 Camptothecin conjugates
CN120665147A (en) 2018-06-14 2025-09-19 味之素株式会社 Compounds having affinity substances for antibodies and bio-orthogonalization functional groups or salts thereof
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
EP3808760A4 (en) 2018-06-14 2022-10-05 Ajinomoto Co., Inc. COMPOUND COMPRISING A SUBSTANCE HAVING AN AFFINITY FOR AN ANTIBODY, CLEAVAGE SITE AND REACTIVE GROUP, OR CORRESPONDING SALT
PE20211091A1 (en) 2018-07-02 2021-06-14 Amgen Inc ANTI-STEAP1 ANTIGEN BINDING PROTEIN
WO2020023871A1 (en) 2018-07-27 2020-01-30 Promega Corporation Quinone-containing conjugates
PL3849614T3 (en) 2018-09-11 2024-04-22 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
EP3852811A1 (en) 2018-09-17 2021-07-28 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
US20220073638A1 (en) 2018-09-19 2022-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
WO2020061498A1 (en) 2018-09-20 2020-03-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
CA3114349A1 (en) 2018-09-26 2020-04-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
CN118903456A (en) 2018-09-26 2024-11-08 江苏恒瑞医药股份有限公司 Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof
KR20210069679A (en) 2018-10-01 2021-06-11 씨젠 인크. Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
CN113366015A (en) 2018-10-19 2021-09-07 Ambrx公司 Interleukin-10 polypeptide conjugates, dimers thereof and uses thereof
TWI824043B (en) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 Drug antibody conjugates
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
TWI844571B (en) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
EP3882261A4 (en) 2018-10-31 2023-02-08 Ajinomoto Co., Inc. COMPOUND WITH SUBSTANCE HAVING AFFINITY FOR ANTIBODY, CLEAVAGE SITE AND REACTIVE GROUP OR SALT THEREOF
EP3647419A1 (en) 2018-11-02 2020-05-06 NBE Therapeutics AG Sortase f and its use in methods for conjugation
JP2022512860A (en) 2018-11-06 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and Pharmaceutical Compositions for the Treatment of Acute Myeloid Leukemia by Eradication of Leukemia Stem Cells
US11279698B2 (en) 2018-11-20 2022-03-22 Cornell University Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
WO2020113108A1 (en) 2018-11-30 2020-06-04 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd38 immunotherapy
AR117652A1 (en) 2018-12-03 2021-08-25 Agensys Inc PHARMACEUTICAL COMPOSITIONS INCLUDING CONJUGATES OF ANTI-191P4D12 ANTIBODY AND DRUG AND METHODS OF USING THEM
KR20210100668A (en) 2018-12-06 2021-08-17 제넨테크, 인크. Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugate, an alkylating agent and an anti-CD20 antibody
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
US20220064260A1 (en) 2018-12-14 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
WO2020127968A1 (en) 2018-12-20 2020-06-25 Marino Stephen F Protein-drug conjugate comprising a monomeric form of proteinase 3
GB201820864D0 (en) * 2018-12-20 2019-02-06 J A Kemp Antibody-drug conjugates
IL312067B2 (en) 2018-12-21 2025-08-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
JP2022523333A (en) 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド Anti-GAL3 antibody and its use
AU2020219732A1 (en) 2019-02-05 2021-08-05 Seagen Inc. Anti-CD228 antibodies and antibody-drug conjugates
US11478553B2 (en) 2019-02-15 2022-10-25 Wuxi Biologies Ireland Limited Process for preparing antibody-drug conjugates with improved homogeneity
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
CN109652384B (en) * 2019-02-21 2021-10-26 昆明理工大学 Method for culturing hepatitis E virus in vitro
PL3930847T3 (en) 2019-02-26 2024-07-08 Inspirna, Inc. High-affinity anti-mertk antibodies and uses thereof
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
CA3132660A1 (en) 2019-03-06 2020-09-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
ES2967878T3 (en) 2019-03-15 2024-05-06 Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
AU2020242284A1 (en) 2019-03-19 2021-09-16 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy for the treatment of cancer
CA3134056A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
CA3134055A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
EP3962951A1 (en) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
WO2020225323A1 (en) 2019-05-06 2020-11-12 Seekyo New therapeutic vectors and prodrugs for treating cancers
AU2020275415B2 (en) 2019-05-14 2026-01-15 Genentech, Inc. Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
CN114096264B (en) 2019-05-20 2025-03-14 因多塞特股份有限公司 Method for preparing PSMA conjugates
CN113874398B (en) 2019-05-21 2025-08-01 诺华股份有限公司 CD19 binding molecules and uses thereof
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
US11052112B2 (en) 2019-05-30 2021-07-06 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-BCMA immunotherapy
US20220233709A1 (en) 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2020247574A1 (en) 2019-06-05 2020-12-10 Seattle Genetics, Inc. Methods of purifying masked antibodies
EP4382129A3 (en) 2019-06-17 2024-07-03 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for high click release speed and yield
EP3994173A1 (en) 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind egfrviii and their use
AU2020318975A1 (en) 2019-07-22 2022-03-17 Seagen Inc. Humanized anti-LIV1 antibodies for the treatment of cancer
CA3146471A1 (en) 2019-08-06 2021-02-11 James K. Kranz Compositions comprising anti-bcma antigen binding proteins for treating bcma-mediated diseases or disorders
MX2022001682A (en) 2019-08-08 2022-05-13 Regeneron Pharma Novel antigen binding molecule formats.
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
US20230218774A1 (en) 2019-09-05 2023-07-13 Pharma Mar, S.A. Drug antibody conjugates
EP4032892A4 (en) 2019-09-18 2023-10-18 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin derivative and conjugate thereof
TWI900494B (en) 2019-09-19 2025-10-11 美商思進公司 Selective drug release from internalized conjugates of biologically active compounds
CN114728046A (en) 2019-09-25 2022-07-08 思进公司 Combination of anti-CD 30 ADC, anti-PD-1 and chemotherapy for treatment of hematologic cancers
EP4036149A4 (en) 2019-09-26 2023-10-25 NOF Corporation HETEROBIFUNCTIONAL MONODISPERSED POLYETHYLENE GLYCOL HAVING A PEPTIDE LINKER
MX2022003517A (en) 2019-10-04 2022-04-25 Seagen Inc ANTI-PD L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES.
CA3154710A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
EP4037710A1 (en) 2019-10-04 2022-08-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3153880A1 (en) 2019-10-18 2020-06-09 Juana Elva HERNANDEZ MONTALVO Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
EP3812008A1 (en) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
WO2021080608A1 (en) 2019-10-25 2021-04-29 Medimmune, Llc Branched moiety for use in conjugates
AU2020379735A1 (en) 2019-11-05 2022-05-26 Regeneron Pharmaceuticals, Inc. N-terminal SCFV multispecific binding molecules
KR20220113685A (en) 2019-11-07 2022-08-16 젠맵 에이/에스 Methods of treating cancer using a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate
TW202131954A (en) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
EP4247957A1 (en) 2019-11-22 2023-09-27 MedImmune Limited Fusion proteins comprising an e2 ubiquitin or ubiquitin-like conjugating domain and a targeting domain for specific protein degradation
EP4684799A2 (en) 2019-12-06 2026-01-28 TrueBinding, Inc. Antibodies that disrupt the interaction of gal3 and insulin receptor or integrins and methods of use thereof
TWI877278B (en) 2019-12-30 2025-03-21 美商思進公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
EP4094779A4 (en) 2020-01-22 2023-11-22 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
EP4114860A1 (en) 2020-03-06 2023-01-11 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
CA3172111A1 (en) 2020-03-19 2021-09-23 Barbora MALECOVA Compositions and methods of treating facioscapulohumeral muscular dystrophy
EP4130045A4 (en) 2020-03-25 2023-12-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for antibody medicament conjugate
WO2021190581A1 (en) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 Pharmaceutical composition comprising antibody drug conjugate and use thereof
EP4126066B1 (en) 2020-03-27 2025-11-19 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
JP2023520773A (en) 2020-03-27 2023-05-19 ノバルティス アーゲー Bispecific combination therapy for treating proliferative and autoimmune diseases
EP4132588A1 (en) 2020-04-10 2023-02-15 Seagen Inc. Charge variant linkers
AU2021260792C1 (en) 2020-04-21 2025-12-04 Pharma Mar, S.A. Drug antibody conjugates
BR112022021441A2 (en) 2020-04-24 2022-12-13 Genentech Inc METHODS TO TREAT FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA AND KITS
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US20230302050A1 (en) 2020-05-20 2023-09-28 Institut Curie Single Domain Antibodies and Their Use in Cancer Therapies
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKADE OF GALECTIN-3
AU2021283714A1 (en) 2020-06-05 2023-01-19 Tessa Therapeutics Ltd. Treatment of CD30-positive cancer
JPWO2021251358A1 (en) 2020-06-09 2021-12-16
US11497770B2 (en) 2020-06-22 2022-11-15 Lentigen Technology, Inc. Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
US20230263902A1 (en) 2020-06-29 2023-08-24 Genmab A/S Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP4189071A1 (en) 2020-08-03 2023-06-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
CN116568337A (en) 2020-08-04 2023-08-08 思进股份有限公司 Anti-CD228 antibodies and antibody-drug conjugates
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc Anti-cd28 compositions
CN112062855B (en) 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 Development and application of drug therapeutic agent containing adapter
WO2022060905A1 (en) 2020-09-15 2022-03-24 The University Of Montana Compositions and methods targeting filamentous bacteriophage
EP3970752A1 (en) 2020-09-17 2022-03-23 Merck Patent GmbH Molecules with solubility tag and related methods
EP4217395A1 (en) 2020-09-28 2023-08-02 Seagen Inc. Humanized anti-liv1 antibodies for the treatment of cancer
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
WO2022099026A1 (en) 2020-11-05 2022-05-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
IL302402A (en) 2020-11-08 2023-06-01 Seagen Inc Combined treatment
CN118878694A (en) 2020-11-23 2024-11-01 康诺亚生物医药科技（成都）有限公司 A bispecific antibody and its use
CN114573702A (en) 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 Development and application of novel tumor adaptor treatment drug
CN114573703A (en) 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 Development and application of T cell adaptor therapeutic agent
JP2023553157A (en) 2020-12-10 2023-12-20 ユーティレックス カンパニー リミテッド Anti-PD-1 antibody and its uses
CA3201178A1 (en) 2020-12-23 2022-06-30 Heinrich Leonhardt Improved cd30 targeting antibody drug conjugates and uses thereof
CN114685657B (en) 2020-12-31 2024-08-16 康诺亚生物医药科技（成都）有限公司 Development and application of a functionally enhanced antibody blocker
CN114716548B (en) 2021-01-05 2024-11-05 (株)爱恩德生物 Anti-FGFR 3 antibodies and uses thereof
WO2022152862A1 (en) 2021-01-14 2022-07-21 Institut Curie Her2 single domain antibodies variants and cars thereof
CA3208290A1 (en) 2021-01-18 2022-07-21 Ajinomoto Co., Inc. Compound or salt thereof, and antibody obtained by using the same
CN116829573A (en) 2021-01-18 2023-09-29 味之素株式会社 Compounds or salts thereof, and antibodies derived therefrom
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
TW202241508A (en) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
EP4297794A2 (en) 2021-02-26 2024-01-03 Forschungsverbund Berlin E.V. Cellular uptake of large biomolecules enabled by cell-surface-reactive cell-penetrating peptide additives
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
JP2024511319A (en) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and CLDN6
JP2024509274A (en) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and GPC3
JP7605290B2 (en) 2021-03-11 2024-12-24 味の素株式会社 Compound or its salt, and antibody obtained therefrom
JPWO2022196675A1 (en) 2021-03-16 2022-09-22
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
EP4308171A1 (en) 2021-03-18 2024-01-24 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
JP2024512567A (en) 2021-03-23 2024-03-19 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） Diagnosis and treatment methods for T-cell lymphoma
US20240191272A1 (en) 2021-03-31 2024-06-13 Microbiopharm Japan Co., Ltd. Method for producing antibody-drug conjugate and enzyme used for the same
US20240382592A1 (en) 2021-04-09 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of anaplastic large cell lymphoma
CA3215049A1 (en) 2021-04-10 2022-10-13 Baiteng ZHAO Folr1 binding agents, conjugates thereof and methods of using the same
CA3216410A1 (en) 2021-04-21 2022-10-27 Guy Dipierro Methods of treatment and dosing of natural killer cell compositions
EP4326768A1 (en) 2021-04-23 2024-02-28 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
EP4326335A1 (en) 2021-04-23 2024-02-28 Forschungsverbund Berlin E.V. Thiol-conjugation with unsaturated phosphorus(v) compounds
US20240376429A1 (en) 2021-04-27 2024-11-14 Baylor College Of Medicine Virus-specific immune cells expressing chimeric antigen receptors
US11931420B2 (en) 2021-04-30 2024-03-19 Celgene Corporation Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
KR20240007184A (en) 2021-05-12 2024-01-16 제넨테크, 인크. Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
AU2022282609A1 (en) 2021-05-26 2023-11-30 Oxford Biotherapeutics Ltd Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
TW202320857A (en) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 Linkers, drug linkers and conjugates thereof and methods of using the same
JP2024526764A (en) 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド How to Prevent Protein Aggregation
EP4370211A1 (en) 2021-07-14 2024-05-22 Seagen Inc. Antibody masking domains
EP4380981A2 (en) 2021-08-03 2024-06-12 GlaxoSmithKline Intellectual Property Development Limited Biopharmaceutical compositions and stable isotope labeling peptide mapping method
EP4380604A1 (en) 2021-08-05 2024-06-12 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN118354789A (en) 2021-09-03 2024-07-16 Go医疗股份有限公司 Anti-glycemic-cMET antibodies and their uses
KR20240051956A (en) 2021-09-03 2024-04-22 도레이 카부시키가이샤 Pharmaceutical composition for treatment and/or prevention of cancer
US20250066498A1 (en) 2021-09-03 2025-02-27 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
KR20240099150A (en) 2021-09-06 2024-06-28 베락사 바이오테크 게엠베하 Novel aminoacyl-tRNA synthetase variants for genetic code expansion in eukaryotes
FR3126982B1 (en) 2021-09-14 2023-09-15 Centre Nat Rech Scient VECTORS TARGETING BETA-D-N-ACETYLGLUCOSAMINIDASE
JP2024535060A (en) 2021-09-16 2024-09-26 アボレリス ファーマ Anti-human CD45RC binding domains and uses thereof
CN118265544A (en) 2021-09-16 2024-06-28 艾维迪提生物科学公司 Compositions and methods for treating facioscapulohumeral muscular dystrophy
US20240376200A1 (en) 2021-09-24 2024-11-14 Seagen Inc. Improved Antibody Masking Domains
CN115975030B (en) 2021-09-30 2023-09-26 杭州邦顺制药有限公司 Anti-CD39 antibody-drug conjugates and their uses
JPWO2023054706A1 (en) 2021-09-30 2023-04-06
AU2022353331A1 (en) 2021-09-30 2024-04-11 Ajinomoto Co., Inc. Regioselective conjugate of functional substance and antibody or salt of said conjugate, and antibody derivative and compound for use in production of said conjugate, or salt of said antibody derivative and compound
TW202321443A (en) 2021-10-26 2023-06-01 新加坡商泰莎治療有限公司 Cell lines for producing a retroviral vector encoding a car
KR20240095442A (en) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 Specific conjugation of antibodies
CA3237371A1 (en) 2021-11-09 2023-05-19 Christian Hackenberger Conjugates comprising a phosphorus (v) and a drug moiety
US20230158154A1 (en) 2021-11-09 2023-05-25 Tubulis Gmbh Conjugates comprising a phosphorus (v) and a camptothecin moiety
EP4429701A4 (en) 2021-11-09 2025-12-31 Truebinding Inc METHOD FOR THE TREATMENT OR INHIBITION OF CARDIOVASCULAR DISEASES
US20250073346A1 (en) 2021-11-18 2025-03-06 Oxford Bio Therapeutics Ltd Pharmaceutical combinations
CA3238167A1 (en) 2021-11-19 2023-05-25 Maria Leia Smith Gpc3 binding agents, conjugates thereof and methods of using the same
DK4186529T3 (en) 2021-11-25 2025-08-25 Veraxa Biotech Gmbh IMPROVED ANTIBODY-PAYLOAD CONJUGATES (APC) MANUFACTURED BY SITE-SPECIFIC CONJUGATION USING GENETIC CODE EXPANSION
AU2022395626A1 (en) 2021-11-25 2024-05-30 Veraxa Biotech Gmbh Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
WO2023104910A1 (en) 2021-12-08 2023-06-15 Tessa Therapeutics Ltd. Treatment of lymphoma
KR20240119102A (en) 2021-12-08 2024-08-06 유럽피안 몰레큘러 바이올로지 래보러토리 Hydrophilic Tetrazine-Functionalized Payload for Preparation of Targeting Conjugates
WO2023110937A1 (en) 2021-12-14 2023-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
JP2025504908A (en) 2022-01-28 2025-02-19 アイオバンス バイオセラピューティクス，インコーポレイテッド Cytokine-associated tumor infiltrating lymphocyte compositions and methods
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
AU2023221765B2 (en) 2022-02-15 2024-09-19 Tagworks Pharmaceuticals B.V. Masked il12 protein
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
WO2023198648A1 (en) 2022-04-11 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t-cell malignancies
TW202346576A (en) 2022-04-13 2023-12-01 新加坡商泰莎治療有限公司 Therapeutic t cell product
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
AU2023262112A1 (en) 2022-04-29 2024-10-31 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
CN119343378A (en) 2022-06-27 2025-01-21 昱言科技(北京)有限公司 Antibodies targeting ITGA2 and antibody-drug conjugates containing the same
TW202408589A (en) 2022-06-30 2024-03-01 美商舒卓生物製藥公司 Anti-ror1 antibodies and antibody conjugates, compositions comprising anti‑ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
JP2025524727A (en) 2022-07-15 2025-07-30 フィアン セラピューティクス エルティーディー Antibody-drug conjugates that bind to CDCP1 and uses thereof
WO2024018046A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
CN119923409A (en) 2022-07-26 2025-05-02 (株)爱恩德生物 Anti-ROR1 antibodies and uses thereof
CN119923410A (en) 2022-07-28 2025-05-02 莱蒂恩技术公司 Chimeric antigen receptor therapy for the treatment of solid tumors
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
EP4536699A4 (en) * 2022-08-22 2025-10-01 Suzhou Bioreinno Biotechnology Ltd Company Method for producing an antibody with thiol group site-specific modifications and use of TCEP
KR20250044409A (en) * 2022-08-22 2025-03-31 수저우 바이오리노 바이오테크놀로지 리미티드 컴퍼니 Method for producing antibodies having site-specific modifications
AU2023329412A1 (en) 2022-08-26 2025-03-20 Lentigen Technology, Inc. Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
AU2023336062A1 (en) 2022-09-02 2025-03-13 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
KR20250069943A (en) 2022-09-21 2025-05-20 씨젠 인크. Antibody that binds to CD228
IL320221A (en) 2022-10-12 2025-06-01 Tagworks Pharmaceuticals B V Strained bicyclononenes
JP2025536268A (en) 2022-10-12 2025-11-05 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル CD81 as a biomarker and biotarget in T-cell malignancies
AU2023364103A1 (en) 2022-10-18 2025-05-29 Tubulis Gmbh Novel antibody drug conjugates with novel napi2b antibodies, therapeutic methods and uses thereof
WO2024083953A1 (en) 2022-10-18 2024-04-25 Tubulis Gmbh Novel anti-tpbg antibody and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
EP4608429A1 (en) 2022-10-25 2025-09-03 Peptomyc, S.L. Combination therapy for the treatment of cancer
CN120417935A (en) 2022-10-25 2025-08-01 默沙东有限责任公司 Exitecan-derived ADC linker-payload and its pharmaceutical composition and use
KR20250089558A (en) 2022-11-03 2025-06-18 씨젠 인크. Anti-αvβ6 antibodies and antibody-drug conjugates and their use in cancer therapy
KR20250117433A (en) 2022-12-13 2025-08-04 크리네틱스 파마슈티칼스, 인크. Somatostatin subtype 2 receptor (SST2R) targeted therapeutic agents and uses thereof
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
AU2023397331A1 (en) 2022-12-14 2025-06-26 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
CN120813386A (en) 2022-12-22 2025-10-17 Tubulis 股份有限公司 Conjugates comprising a phosphorus (V) moiety and a drug
IL322053A (en) 2023-01-13 2025-09-01 Regeneron Pharma Fgfr3 binding molecules and methods of use thereof
CN120569216A (en) 2023-01-20 2025-08-29 巴斯夫欧洲公司 Stabilized biopolymer compositions, their manufacture and use
WO2024165484A1 (en) 2023-02-06 2024-08-15 Institut National de la Santé et de la Recherche Médicale Enrichment of genetically modified hematopoietic stem cells through multiplex base editing
WO2024165045A1 (en) 2023-02-09 2024-08-15 Beigene, Ltd. Self-stabilizing linker conjugates
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
KR20250169530A (en) 2023-03-10 2025-12-03 태그웍스 파마슈티컬스 비.브이. Trans-cyclooctene with improved T-linker
AU2024238898A1 (en) 2023-03-22 2025-10-16 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof
WO2024194851A1 (en) 2023-03-23 2024-09-26 Beigene Switzerland Gmbh Bioactive conjugate, preparation method therefor and use thereof
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
KR20250172615A (en) 2023-04-04 2025-12-09 아지노모토 가부시키가이샤 Conjugates of antibodies and functional substances, antibody derivatives and compounds, or salts thereof
JPWO2024210178A1 (en) 2023-04-05 2024-10-10
CN116239513B (en) * 2023-05-05 2023-08-18 天津凯莱英制药有限公司 The preparation method of the key intermediate of MMAE, the preparation method of MMAE and antibody-conjugated drug
CN121285392A (en) 2023-05-09 2026-01-06 上海复宏汉霖生物技术股份有限公司 Anti-PDL 1 antibody-drug conjugate and application thereof
AU2024269443A1 (en) 2023-05-09 2025-12-11 Shanghai Henlius Biologics Co., Ltd. Anti-epidermal growth factor receptor (egfr) antibody-drug conjugate and use thereof
WO2024236156A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d antibodies
CN121311503A (en) 2023-06-02 2026-01-09 昱言科技(北京)有限公司 ITGA 2-targeting antibodies, antibody drug conjugates and uses thereof
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
AU2024285758A1 (en) 2023-06-07 2025-12-18 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
TW202513088A (en) 2023-06-07 2025-04-01 瓦爾希伯倫私人腫瘤研究基金會 Combination therapy with mek inhibitors for the treatment of cancer
CN121285742A (en) 2023-06-08 2026-01-06 基因泰克公司 Macrophage characterization for diagnostic and therapeutic methods of lymphoma
AU2024304180A1 (en) 2023-06-13 2026-01-08 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
WO2025005651A1 (en) 2023-06-27 2025-01-02 아테온바이오 주식회사 Humanized anti-myct1 antibody and use thereof
AU2024296940A1 (en) 2023-07-07 2026-01-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
AU2024296516A1 (en) 2023-07-13 2026-01-22 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025021928A1 (en) 2023-07-25 2025-01-30 Merck Patent Gmbh Iduronidase-cleavable compounds
AU2024300552A1 (en) 2023-07-27 2026-01-29 Veraxa Biotech Gmbh Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
WO2025056807A1 (en) 2023-09-15 2025-03-20 Basf Se Stabilized biopolymer composition, their manufacture and use
AU2024201132A1 (en) 2023-09-20 2025-04-10 Uci Therapeutics Inc. Anti-mesothelin antibodies and uses thereof
TW202535954A (en) 2023-09-26 2025-09-16 丹麥商珍美寶股份有限公司 Ptk7 binding agents, conjugates thereof and methods of using the same
WO2025081117A2 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025151608A1 (en) * 2024-01-10 2025-07-17 Systimmune, Inc. Connecting units for ligand-drug conjugates and methods of making and using thereof
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025163468A1 (en) 2024-01-30 2025-08-07 Seagen Inc. Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
WO2025174248A1 (en) 2024-02-16 2025-08-21 Tagworks Pharmaceuticals B.V. Trans-cyclooctenes with "or gate" release
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
US20250295801A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody drug conjugates, and uses thereof
EP4624494A1 (en) 2024-03-29 2025-10-01 Institut Curie Her2 single domain antibody and uses thereof
WO2025223455A1 (en) 2024-04-24 2025-10-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ptk7/b7h3 antibodies and uses thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025238052A1 (en) 2024-05-15 2025-11-20 Institut National de la Santé et de la Recherche Médicale Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2025248500A1 (en) 2024-05-31 2025-12-04 Janssen Biotech, Inc. Antibody drug conjugates that target enpp3
WO2025248097A2 (en) 2024-05-31 2025-12-04 Gamamabs Pharma Humanized anti-human her3 antibodies and uses thereof
WO2025257394A1 (en) 2024-06-14 2025-12-18 BioNTech SE Combination therapy for cancer treatment
WO2025264533A1 (en) 2024-06-17 2025-12-26 Adcentrx Therapeutics Inc. Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
US20260000765A1 (en) 2024-06-27 2026-01-01 Lentigen Technology, Inc. CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3445518A (en) 1966-05-06 1969-05-20 Warner Lambert Pharmaceutical P-acylphenylethylamines
US4414205A (en) 1981-08-28 1983-11-08 University Patents, Inc. Cell growth inhibitory substances
ES8504461A1 (en) 1982-04-12 1985-04-16 Hybritech Inc Antibodies having dual specificities, their preparation and uses therefor.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4764368A (en) * 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
JPH01202700A (en) 1988-02-09 1989-08-15 Mitsubishi Electric Corp X-ray mirror and its manufacturing method
FI102355B1 (en) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Process for Preparation of Anthracycline Immunoconjugates with a Linking Link
US4943628A (en) 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
SG52662A1 (en) 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5165923A (en) 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
US5767236A (en) 1990-05-09 1998-06-16 Biomeasure, Inc. Linear therapeutic peptides
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (en) 1990-08-29 1998-02-19 Genpharm Int Production and Use Non-human transgene heterologous antibodies for production
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2115355C (en) 1991-08-09 2007-09-11 Kyoichi Sakakibara Novel tetrapeptide derivative
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ATE149570T1 (en) 1992-08-17 1997-03-15 Genentech Inc BISPECIFIC IMMUNOADHESINS
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH06234790A (en) 1993-02-09 1994-08-23 Teikoku Hormone Mfg Co Ltd Novel tetrapeptide amide derivative
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
FR2710536B1 (en) 1993-09-29 1995-12-22 Transgene Sa Anti-cancer use of a viral vector comprising a gene which modulates the immune and / or inflammatory response.
US5767237A (en) 1993-10-01 1998-06-16 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
ES2141467T5 (en) 1995-01-18 2006-07-16 Roche Diagnostics Gmbh ANTI-CD30 ANTIBODIES THAT AVOID THE PROTEOLITIC EXCISION AND RELEASE OF THE CD30 ANTIGEN FIXED TO THE MEMBRANE.
AU704973B2 (en) 1995-04-21 1999-05-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
JPH0977791A (en) 1995-09-08 1997-03-25 Nippon Kayaku Co Ltd Peptide derivative and its use
SE9503380D0 (en) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5741892A (en) 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
DE69832158T2 (en) 1997-02-25 2006-08-10 Arizona Board Of Regents, Tempe ISOLATION AND STRUCTURAL EXPLANATION OF CRYOSTATIC LINEARS AND CYCLO DEPSIPEPTIDES DOLASTATIN 16, DOLASTATIN 17, AND DOLASTATIN 18
US5965537A (en) 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
WO1999035164A1 (en) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Anti-cryptococcal peptides
US6162930A (en) 1998-03-06 2000-12-19 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
ATE412433T1 (en) * 1999-02-12 2008-11-15 Scripps Research Inst METHODS OF TREATING TUMORS AND METASTASIS USING ANTI-ANGIogenic AND IMMUNE THERAPIES
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
JP2003528805A (en) * 1999-07-12 2003-09-30 ジェネンテック・インコーポレーテッド Blocking an immune response to a heterologous antigen using an antagonist that binds to CD20
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
PL357939A1 (en) * 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
US20040235068A1 (en) 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
US20050123536A1 (en) * 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
IL163573A0 (en) 2002-03-01 2005-12-18 Univ Tulane Conjugates of therapeutic or cytotoxic agents and biologically active peptides
ATE395082T1 (en) 2002-03-08 2008-05-15 Pdl Biopharma Inc ANTIBODIES TO CANCER ANTIGEN TMEFF2 AND ITS APPLICATIONS
AU2003228336B2 (en) 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
PT2357006E (en) 2002-07-31 2016-01-22 Seattle Genetics Inc Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2003294210A1 (en) 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
JP2006500364A (en) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド Crosslinkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
ES2388280T3 (en) 2002-12-20 2012-10-11 Abbott Biotherapeutics Corp. Antibodies that react to GPR64 and use them
WO2004073656A2 (en) 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
JP2007525434A (en) 2003-03-19 2007-09-06 アブジェニックス インコーポレイテッド Antibodies to T cells, immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof.
PT1725249E (en) 2003-11-06 2014-04-10 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CA2558399C (en) 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US7399469B2 (en) 2004-03-26 2008-07-15 Pdl Biopharma, Inc. Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
US7442332B2 (en) * 2004-05-04 2008-10-28 Clopay Plastic Products Company, Inc. Method and apparatus for uniformly stretching thermoplastic film and products produced thereby
CN1960965A (en) 2004-06-02 2007-05-09 霍夫曼-拉罗奇有限公司 Synthesis of amino-alkoxy-heptanoic alkyl ester
BRPI0516284A (en) 2004-09-23 2008-09-02 Genentech Inc cysteine-constructed antibody, method of selecting antibodies, drug-antibody conjugated compounds, pharmaceutical composition, method for killing or inhibiting tumor cell proliferation, methods of inhibiting cell proliferation and tumor cell growth, manufactured article and method to produce a compound
MX2007003907A (en) 2004-10-05 2007-05-21 Genentech Inc Therapeutic agents with decreased toxicity.
AU2005322410B2 (en) 2004-11-30 2011-11-10 Amgen Fremont Inc. Antibodies directed to GPNMB and uses thereof
JP2008523001A (en) 2004-12-13 2008-07-03 エフ．ホフマン−ラ ロシュ アーゲー Novel process for preparing 3-pyrrolidin-2-yl-propionic acid derivatives
WO2006083936A2 (en) 2005-01-31 2006-08-10 Genentech, Inc. Anti-ephb2 antibodies and methods using same
US20070098715A1 (en) 2005-03-25 2007-05-03 Seth Ettenberg Antibodies against the tenascin major antigens
PT1912677E (en) 2005-06-20 2013-12-23 Psma Dev Company L L C Psma antibody-drug conjugates
JP2009506790A (en) 2005-09-07 2009-02-19 メディミューン，エルエルシー EPH receptor antibody conjugated to toxin
JP2009515897A (en) 2005-11-10 2009-04-16 キュラジェン コーポレイション Methods of treating ovarian and renal cancer using antibodies to immunoglobulin domains of murine domain and mucin domain 1 (TIM-1) antigen
WO2007062138A2 (en) 2005-11-23 2007-05-31 Applera Corporation Methods and compositions for treating diseases targeting human prominin-1(cd133)
DOP2006000277A (en) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp ANTI MN ANTIBODIES AND METHODS FOR USE
AR059900A1 (en) 2006-03-17 2008-05-07 Genentech Inc ANTI-TAT226 ANTIBODIES AND IMMUNOCATE PLAYERS

Also Published As

Publication number Publication date
PT2357006E (en) 2016-01-22
EP2353611A2 (en) 2011-08-10
CA2494105A1 (en) 2004-02-05
EP2353611B1 (en) 2015-05-13
EP1545613B9 (en) 2012-01-25
ES2544527T3 (en) 2015-09-01
EP1545613B1 (en) 2011-07-20
US7851437B2 (en) 2010-12-14
US7829531B2 (en) 2010-11-09
EP2357006B1 (en) 2015-09-16
LU92133I2 (en) 2013-03-18
CA2494105C (en) 2013-04-02
WO2004010957A3 (en) 2004-06-10
CY1111894T1 (en) 2015-11-04
CA2802205C (en) 2016-01-19
AU2003263964A1 (en) 2004-02-16
SI2357006T1 (en) 2016-01-29
EP2357006A3 (en) 2011-10-19
US8906376B2 (en) 2014-12-09
DK1545613T3 (en) 2011-11-14
US7659241B2 (en) 2010-02-09
AU2003263964C1 (en) 2010-08-19
US20110064753A1 (en) 2011-03-17
LU92133I9 (en) 2019-01-04
WO2004010957A2 (en) 2004-02-05
FR12C0066I2 (en) 2013-08-16
ES2369542T3 (en) 2011-12-01
WO2004010957B1 (en) 2004-08-19
EP1545613A2 (en) 2005-06-29
HK1157180A1 (en) 2012-06-29
EP2357006A2 (en) 2011-08-17
SI1545613T1 (en) 2011-11-30
JP2006500333A (en) 2006-01-05
FR12C0066I1 (en) 2012-12-14
US20090324621A1 (en) 2009-12-31
US20060074008A1 (en) 2006-04-06
CY2013004I2 (en) 2017-09-13
CY2013004I1 (en) 2015-11-04
US20080213289A1 (en) 2008-09-04
PT1545613E (en) 2011-09-27
AU2010201459A1 (en) 2010-05-06
AU2010201459B2 (en) 2012-12-06
CA2802205A1 (en) 2004-02-05
ATE516818T1 (en) 2011-08-15
EP1545613A4 (en) 2008-10-15
US20100062008A1 (en) 2010-03-11
ES2556641T3 (en) 2016-01-19
EP2353611A3 (en) 2011-10-19
AU2003263964B2 (en) 2010-01-14
DK2357006T3 (en) 2015-12-21
HUE027549T2 (en) 2016-10-28
HUS1300002I1 (en) 2016-08-29
JP4741838B2 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
LU92133I9 (en)
CY1125064T1 (en) BETA-GLYCURONIDE DRUG CONJUGATIONS
DK1594542T3 (en) Anti-CD70 antibody-drug conjugates and their use in the treatment of cancer
MY137552A (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
PL374523A1 (en) Calicheamicin derivative-carrier conjugates
WO2007100385A3 (en) Macrocyclic depsipeptide antibody-drug conjugates and methods
WO2005032454A3 (en) Anti-muc-1 single chain antibodies for tumor targeting
CY1117387T1 (en) Monoclonal N-11 Dispersed β-Amyloid Antibodies, COMPOSITIONS, METHODS AND USES
DK1660650T3 (en) Enhanced Sso7 polymerase conjugate proteins
PL1797893T3 (en) Antibodies against phosphorylcholine conjugates
EP1572087A4 (en) Antibodies against cancer antigen tmeff2 and uses thereof
DE60113445D1 (en) SUBSTANCES WITH BRANCHED LINKERMOLEKÜLEN
WO2005000858A3 (en) Bisphosphonate complexes
WO2004069206A3 (en) Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
ATE280588T1 (en) DEXTRAN-LEPTIN CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
MXPA01010395A (en) Cobalamin conjugates useful as antitumor agents.
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
CY1117037T1 (en) AURISTATIN COGNITIVE PRODUCTS AND USE THEM FOR CANCER, SELF-DIVERSITY OR POLLUTIONAL DISEASE TREATMENT
PT1708693E (en) Pharmaceutical compositions containing paltinum complexes with secondary xanthates and therapeutic uses thereof
WO2004069207A3 (en) Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
AU2002354872A1 (en) Novel chelating agents and conjugates thereof, their synthesis and use as diagnostic and therapeutic agents